- Home
- CABA vs VNDA Comparison
CABA vs VNDA Comparison
Compare CABA & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- VNDA
- Stock Information
- Founded
- CABA 2017
- VNDA 2002
- Country
- CABA United States
- VNDA United States
- Employees
- CABA N/A
- VNDA N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- CABA Health Care
- VNDA Health Care
- Exchange
- CABA Nasdaq
- VNDA Nasdaq
- Market Cap
- CABA 233.2M
- VNDA 260.0M
- IPO Year
- CABA 2019
- VNDA 2006
- Fundamental
- Price
- CABA $2.32
- VNDA $4.36
- Analyst Decision
- CABA Strong Buy
- VNDA Strong Buy
- Analyst Count
- CABA 8
- VNDA 3
- Target Price
- CABA $13.50
- VNDA $14.00
- AVG Volume (30 Days)
- CABA 5.3M
- VNDA 675.7K
- Earning Date
- CABA 11-10-2025
- VNDA 10-29-2025
- Dividend Yield
- CABA N/A
- VNDA N/A
- EPS Growth
- CABA N/A
- VNDA N/A
- EPS
- CABA N/A
- VNDA N/A
- Revenue
- CABA N/A
- VNDA $212,074,000.00
- Revenue This Year
- CABA N/A
- VNDA $14.32
- Revenue Next Year
- CABA N/A
- VNDA $37.05
- P/E Ratio
- CABA N/A
- VNDA N/A
- Revenue Growth
- CABA N/A
- VNDA 11.12
- 52 Week Low
- CABA $0.99
- VNDA $3.81
- 52 Week High
- CABA $5.46
- VNDA $5.70
- Technical
- Relative Strength Index (RSI)
- CABA 44.66
- VNDA 34.76
- Support Level
- CABA $2.30
- VNDA $4.35
- Resistance Level
- CABA $2.67
- VNDA $4.48
- Average True Range (ATR)
- CABA 0.33
- VNDA 0.20
- MACD
- CABA -0.07
- VNDA -0.05
- Stochastic Oscillator
- CABA 8.05
- VNDA 5.59
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.